---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-23-000127"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:45:57.925252+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M

## Summary
- Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).
- Total test reports 16,820 (+52%); DecisionDx-SCC +99%, TissueCypher +311%, IDgenetix +224%.
- Net loss $(18.8)M includes $12.8M stock comp; adjusted EBITDA improves to $(5.3)M from $(11.2)M.
- Raises 2023 revenue guidance to at least $180M from prior $170-180M.
- Cash and investments $225.5M; net operating cash use improved to $3.8M from $9.0M.

## SEC filing metadata
- accession: 0001447362-23-000127
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/0001447362-23-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/cstl-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-23-000127
- JSON: https://secwatch.observer/filing/0001447362-23-000127.json
- Plain text: https://secwatch.observer/filing/0001447362-23-000127.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported second quarter and six months ended June 30, 2023 results: revenue $50.1 million, net income $(18.8) million. Guidance raised.
  - Period: second quarter and six months ended June 30, 2023
  - Revenue: $50.1 million
  - Net income: $(18.8) million
  - Guidance: raised
  - Result: reported results
  source text: such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/0001447362-23-000127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.